Marina Deodato

528 total citations
13 papers, 99 citations indexed

About

Marina Deodato is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Marina Deodato has authored 13 papers receiving a total of 99 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Marina Deodato's work include Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Marina Deodato is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (9 papers) and Immunodeficiency and Autoimmune Disorders (5 papers). Marina Deodato collaborates with scholars based in Italy, Switzerland and United States. Marina Deodato's co-authors include Alessandra Tedeschi, Anna Maria Frustaci, Roberto Cairoli, Marco Montillo, Barbara Di Camillo, Antonino Greco, Alessandra Trojani, Alessandro Beghini, Davide Rossi and Pier Luigi Zinzani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancers.

In The Last Decade

Marina Deodato

13 papers receiving 98 citations

Peers

Marina Deodato

GENET

PFM

IMMUN

HEMAT

Anouk de Jong United States

Yufu Lin China

Jennie Zhang United States

Danielle Leão Cordeiro de Farias Brazil

Éric Durot France

Krista M. Isaac United States

Zachary A. Hing United States

Ganna Usenko Ukraine

Iryna Kriachok Ukraine

С. В. Семочкин Russia

Anouk de Jong United States

Marina Deodato

99 ×1.3

GENET

66 ×1.2

PFM

29 ×0.7

26 ×1.2

IMMUN

39 ×2.2

HEMAT

Citations per year, relative to Marina Deodato Marina Deodato (= 1×) peers Anouk de Jong

Countries citing papers authored by Marina Deodato

Since Specialization

Citations

This map shows the geographic impact of Marina Deodato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Deodato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Deodato more than expected).

Fields of papers citing papers by Marina Deodato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Deodato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Deodato. The network helps show where Marina Deodato may publish in the future.

Co-authorship network of co-authors of Marina Deodato

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Deodato. A scholar is included among the top collaborators of Marina Deodato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Deodato. Marina Deodato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Deodato, Marina, Anna Maria Frustaci, Carlo Gambacorti‐Passerini, et al.. (2024). Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia. Leukemia & lymphoma. 65(14). 2096–2107. 1 indexed citations

Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. HemaSphere. 7(S3). e6990566–e6990566. 1 indexed citations

Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME. Hematological Oncology. 41(S2). 62–63. 2 indexed citations

Frustaci, Anna Maria, et al.. (2023). Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. Cancers. 15(5). 1504–1504. 31 indexed citations

Frustaci, Anna Maria, Marco Montillo, Davide Rossi, et al.. (2023). Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome.. Journal of Clinical Oncology. 41(16_suppl). 7502–7502. 5 indexed citations

Frustaci, Anna Maria, et al.. (2021). SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?. Clinical Lymphoma Myeloma & Leukemia. 22(6). 356–361. 1 indexed citations

Trojani, Alessandra, Barbara Di Camillo, Antonino Greco, et al.. (2021). Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells. Cancers. 13(8). 1837–1837. 7 indexed citations

Frustaci, Anna Maria, et al.. (2020). Duvelisib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy. 21(11). 1299–1309. 14 indexed citations

Frustaci, Anna Maria, et al.. (2019). Duvelisib: A New Phosphoinositide-3-Kinase Inhibitor in Chronic Lymphocytic Leukemia. Future Oncology. 15(19). 2227–2239. 17 indexed citations

10.

Deodato, Marina, et al.. (2019). Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology. 12(5). 273–284. 3 indexed citations

11.

Frustaci, Anna Maria, Michele Nichelatti, Marina Deodato, et al.. (2018). Health-Related Quality of Life in Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undeterminated Significance (IgM-MGUS). Blood. 132(Supplement 1). 3593–3593. 1 indexed citations

12.

Frustaci, Anna Maria, et al.. (2017). WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE. Mediterranean Journal of Hematology and Infectious Diseases. 10(1). e2018004–e2018004. 15 indexed citations

13.

Frustaci, Anna Maria, et al.. (2017). Ibrutinib and its use in the Treatment of Chronic Lymphocytic Leukemia. Future Oncology. 14(8). 681–697. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact